# Review group to be set up to consider protocol on administration of medicinal cannabis in hospitals > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/hospital-medicinal-cannabis-protocols-treatment-continuity/ > **Published:** 2026-04-24T16:04:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:11:26-04:00 > **Clinical Summary:** Hospital medicinal cannabis protocols are essential for maintaining treatment continuity and preventing withdrawal during inpatient care. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Hospital Medicine[Healthcare Policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/)Treatment ContinuityClinical ProtocolsMedicinal Cannabis Why This Matters Hospital-based medicinal cannabis protocols represent a critical gap in clinical care, as patients often face treatment interruptions during acute admissions. Standardized administration guidelines could prevent withdrawal symptoms and maintain therapeutic continuity for patients already established on cannabis treatments. Clinical Summary Ireland is establishing a review group to develop protocols for medicinal cannabis administration in hospital settings. This addresses the current lack of standardized procedures for continuing [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) during inpatient care. The initiative recognizes that patients on prescribed medicinal cannabis require consistent access to their medications during hospitalization, similar to other prescribed therapeutics. Dr. Caplan’s Take “This is exactly what we need to see more of — treating medicinal cannabis like any other prescribed medication that requires continuity of care. Hospital protocols remove the guesswork and protect both patients and providers.” Clinical Perspective 🧠 Clinicians should advocate for similar protocol development in their institutions, as treatment interruptions can lead to symptom recurrence and patient distress. This represents a maturation of medicinal cannabis integration into mainstream healthcare delivery systems. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Review%20group%20to%20be%20set%20up%20to%20consider%20protocol%20on%20administration%20of%20medicinal%20ca...%20%40drcaplan&url=https%3A//www.irishexaminer.com/news/arid-41833238.html)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.irishexaminer.com/news/arid-41833238.html)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Review%20group%20to%20be%20set%20up%20to%20consider%20protocol%20on%20administration%20of%20medicinal%20ca...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.irishexaminer.com/news/arid-41833238.html)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.irishexaminer.com/news/arid-41833238.html](https://www.irishexaminer.com/news/arid-41833238.html) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis-related development?](#What_is_the_clinical_relevance_rating_of_this_cannabis-related_development) - [Which medical specialties are most affected by this cannabis news?](#Which_medical_specialties_are_most_affected_by_this_cannabis_news) - [What type of cannabis-related development is being reported?](#What_type_of_cannabis-related_development_is_being_reported) - [How does this affect treatment continuity for patients?](#How_does_this_affect_treatment_continuity_for_patients) - [Why should healthcare professionals pay attention to this development?](#Why_should_healthcare_professionals_pay_attention_to_this_development) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis-related development? This development has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments that healthcare professionals should monitor closely. #### Which medical specialties are most affected by this cannabis news? Hospital Medicine is the primary specialty affected, along with broader [healthcare policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/) implications. The development appears to impact clinical protocols and treatment continuity across hospital settings. #### What type of cannabis-related development is being reported? This appears to be an emerging policy or clinical finding related to cannabis use in hospital medicine settings. The classification suggests it involves new protocols or treatment approaches worth monitoring. #### How does this affect treatment continuity for patients? The development appears to have implications for maintaining consistent cannabis-related treatment protocols during hospital stays. This could affect how [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) patients receive care during hospitalization. #### Why should healthcare professionals pay attention to this development? The “Notable Clinical Interest” rating indicates this represents an emerging trend in cannabis policy or clinical practice. Healthcare providers should monitor these developments as they may influence future treatment protocols and patient care standards. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Most-prescribed medicinal cannabis type 'not supported by evidence' | AusDoc](https://cedclinic.com/most-prescribed-medicinal-cannabis-type-evidence-review/) Explore evidence-based insights on the most commonly prescribed medicinal cannabis types and their clinical support. [Read the analysis](https://cedclinic.com/most-prescribed-medicinal-cannabis-type-evidence-review/) [Commercial Insurance Has Failed Cannabis. Here's What's Next](https://cedclinic.com/cannabis-insurance-coverage-gaps-whats-next/) Understand the challenges and future directions of commercial insurance in the cannabis industry. [Learn more](https://cedclinic.com/cannabis-insurance-coverage-gaps-whats-next/) [CMS unveils new Medicare pilot for hemp, CBD products – Fierce Healthcare](https://cedclinic.com/medicare-pilot-hemp-cbd-coverage-expands-access/) Discover the latest Medicare pilot program focusing on hemp and [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) and its implications for patient care. [Explore details](https://cedclinic.com/medicare-pilot-hemp-cbd-coverage-expands-access/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).